Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Michigan Supplemental Rebate Program Takes “Best In Class” Approach

Executive Summary

The Michigan Medicaid supplemental rebate program requires manufacturers to match the price of "best-in-class" agents or be subject to prior authorization

You may also be interested in...



Michigan Rx List Is More Restrictive Than Private Plans, Kaiser Study Says

The Michigan Medicaid preferred drug list is more restrictive in several therapeutic categories than other pharmacy benefit plans, a Kaiser Family Foundation study says

Michigan Rx List Is More Restrictive Than Private Plans, Kaiser Study Says

The Michigan Medicaid preferred drug list is more restrictive in several therapeutic categories than other pharmacy benefit plans, a Kaiser Family Foundation study says

Michigan Rx Rebate Program Upheld In State Court; Federal Suit Pending

Michigan Medicaid's statutory authority to collect supplemental rebates has been upheld by the Michigan Court of Appeals

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038902

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel